DESCOVY (emtricitabine, tenofovir alafenamide), antiretroviral combination

Opinions on drugs - Posted on Jul 12 2017

Reason for request


No clinical benefit demonstrated for this second-line treatment in the treatment of HIV infection.


  • DESCOVY, in combination with other antiretrovirals, has the Marketing Authorisation in the treatment of adults and adolescents (aged 12 years and older, weighing at least 35 kg) infected with type 1 human immunodeficiency virus (HIV-1).
  • In adults, it is an alternative to TRUVADA (emtricitabine, tenofovir disoproxil fumarate).
  • In adolescents and patients with moderate renal failure (estimated creatinine clearance ≥ 30 mL/min), it is a therapeutic option only in cases in which it is not possible to prescribe first-line medicinal products that are not associated with a risk of kidney and bone damage.
  • It must be used alongside monitoring of renal function, calcium and phosphorus metabolism, and lipid parameters.



Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments